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Background: Septic shock remains a leading cause of death, despite advances in critical care management. The Surviving Sepsis 
Campaign (SSC) has reduced morbidity and mortality. This study evaluated risk factors for mortality in patients with septic shock 
who received treatment following the SSC bundles.
Materials and Methods: This retrospective cohort study included patients with septic shock who received treatments following 
SSC bundles in an urban emergency department between November 2007 and November 2011. Primary and secondary end-
points were all-cause 7- and 28-day mortality.
Results: Among 436 patients, 7- and 28-day mortality rates were 7.11% (31/436) and 14% (61/436), respectively. In multivariate 
analysis, high lactate level (odds ratio [OR], 1.286; 95% confidence interval [CI], 1.016-1.627; P = 0.036) and low estimated 
glomerular filtration rate (OR, 0.953; 95% CI, 0.913-0.996; P = 0.032) were independent risk factors for 7-day mortality. Risk 
factors for 28-day mortality were high lactate level (OR, 1.346; 95% CI, 1.083-1.673; P = 0.008) and high Acute Physiology 
and Chronic Health Evaluation II score (OR, 1.153; 95% CI, 1.029-1.293; P = 0.014). 
Conclusion: The risk of mortality of septic shock patients remains high in patients with high lactate levels and acute kidney injury.
Key Words: Septic shock; Risk factors; Mortality
Original Article
07-원저-16-580 송제은-최준용.indd   1 2016-09-29   오후 1:51:02
Song JE, et al. • Mortality risk factors for sepsis patients www.icjournal.org200
Introduction
Septic shock remains a leading cause of death, despite ad-
vances in critical care management [1]. Septicemia is current-
ly ranked as the 11th leading cause of death in the United 
States [1]. In 2001, Rivers et al. [2] showed that early goal-di-
rected therapy (EGDT) could decrease mortality in patients 
with severe sepsis and septic shock. Since that initial report, 
multiple studies have provided evidence that EGDT reduces 
morbidity and mortality in patients with septic shock [3-5]. 
Because of the surprising benefit of the Surviving Sepsis Cam-
paign (SSC) resuscitation bundle in decreasing mortality, our 
institute implemented EGDT and SSC resuscitation bundles 
using a multidisciplinary team model [6].
However, there were several findings about mortality of EG-
DT-based bundle therapy than usual care [7-9]. Yearly et al. 
performed a randomized multicenter trial for 1,341 patients. 
And they found that there were no significant differences in 
60-day mortality among protocol-based EGDT, proto-
col-based standard therapy and usual care [7].
Because there is controversy about benefits of implementa-
tion of SSC bundles clearly helps to decrease mortality, further 
improvement of the survival of patients with septic shock re-
quires the identification of subgroups with risks of mortality. 
Thus, we aimed to identify risk factors for mortality in patients 
with septic shock who were treated with SSC bundles. 
Materials and Methods
1. Surviving sepsis campaign bundle implementation 
and study population
This retrospective cohort study was conducted at a tertiary 
care teaching hospital in Seoul, South Korea. We reviewed the 
medical records and laboratory data of all patients with septic 
shock who received treatment following SSC bundles between 
November 2007 and November 2011. The data were retro-
spectively collected using standardized forms. 
Since November 2007, SSC bundles have been implement-
ed in the intensive care units (ICUs) and emergency depart-
ment (ED) of our institute as part of a quality improvement 
initiative. Our hospital is a 2,000-bed academic hospital, with 
a total of 105 ICU beds (53 medical/surgical, 22 dedicated to 
cardiothoracic surgery and cardiology, and 30 for neurosci-
ence).
The process of screening a patient for SSC bundle began 
with the ED physician. Eligibility for SSC bundle was assessed 
in patients with two or more systemic inflammatory response 
syndrome criteria and suspected infection in emergency de-
partment. Initiation of our SSC protocol was triggered by (a) 
initial systolic blood pressure <90 mmHg, despite a 20mL/kg 
intravenous crystalloid fluid challenge; and/or (b) initial se-
rum lactate level ≥4 mmol/L. The exclusion criteria were: (a) 
age <15 years, (b) contraindication to central venous catheter-
ization, and (c) do-not-resuscitate (DNR) status. When appro-
priate, collaborative teams were notified via mobile telephone 
that a patient met all criteria. The patient was transferred to 
the ICU as soon as possible, and an infectious disease physi-
cian selected an appropriate empiric antibiotic. This process 
included the initiation of an aggressive, evidence-based care 
protocol focused on achieving a mean arterial pressure (MAP) 
≥65 mmHg, central venous pressure (CVP) ≥8 mmHg, and 
central venous oxygen saturation ≥70% within 6 h.
Based on the best practices at the time, our SSC protocol also 
included recommendations for the use of stress-dose steroids 
for patients with refractory shock, low-tidal-volume ventilation 
for acute lung injury or acute respiratory distress syndrome 
(ARDS), and intravenous insulin to control hyperglycemia 
with a validated protocol for dose adjustment. However, we 
did not use activated protein C because it was not available in 
Korea. 
2. Variables and definitions
Data on patients’ demographic characteristics, clinical vari-
ables, and hospital resources used were collected, including 
the duration(in days) of hospitalization, age, sex, body mass 
index, vital signs, underlying disease, site of infection, severity 
of illness (classified using Acute Physiology and Chronic 
Health Evaluation II (APACHE II) [10] and Sequential Organ 
Failure Assessment (SOFA) [11] scores at the time of ER pre-
sentation), laboratory results, antimicrobial therapy regimen, 
in vitro effectiveness of empirical antimicrobial agents, isolat-
ed pathogens, and antimicrobial susceptibility of bacteria. In 
addition, we assessed data related to the sepsis-specific thera-
pies that were applied, such as transfusion, ventilator care, he-
modialysis, and corticosteroid, insulin, and antithrombin use. 
Severe sepsis was defined as sepsis associated with organ dys-
function, hypoperfusion, or hypotension [12]. Hypoperfusion 
and hypotension abnormalities included, but were not limited 
to, lactic acidosis, oliguria, and acute alteration of mental sta-
tus. Septic shock was defined as sepsis-induced hypotension 
despite adequate fluid resuscitation in the presence of perfu-
sion abnormalities [12]. Patients who were receiving vasopres-
sor agents were considered to have hypotension, regardless of 
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hypotensive status at the time of perfusion abnormality mea-
surement. Neutropenia was defined as an absolute neutrophil 
count <500 cells/mm3 [13]. Standard Centers for Disease Con-
trol nosocomial infection definitions were used to define the 
sites of infection [14].
ARDS was defined according to the classification of the 
American European Consensus Conference [15]. Initial anti-
microbial therapy was considered to have been appropriate 
when all causative microorganisms were susceptible at least 
one administered antimicrobial agent within 24 h of culture 
sample acquisition [16]. Inappropriate therapy referred to the 
administration of an antimicrobial agent to which at least one 
causative microorganism was resistant, or to the lack of anti-
microbial therapy for the known causative pathogen. Therapy 
was also considered inappropriate when the antimicrobial 
agent was not administered within 24 h of primary microbial 
isolation from blood or a remote site of infection. The admin-
istration of aminoglycoside monotherapy for non-fermenting 
gram-negative bacilli was considered inappropriate [17].
3. Data analyses
The primary and secondary endpoints were all-cause 7-and 
28-day mortality. 
Continuous variables are presented as means (standard de-
viation [SD]) or medians (inter-quartile range [IQR]), and cat-
egorical variables are presented as numbers and percentages. 
For continuous variables, Student’s t test or the Mann-Whit-
ney U test was used depending on the validity of the normality 
assumption. The chi-square test or Fisher’s exact test was used 
to assess categorical variables. Potential risk factors for mor-
tality were evaluated by univariate analysis, and factors with 
P-values <0.05 were included in a multivariate model. To 
identify independent risk factors for mortality, Cox regression 
analysis was used to control for the effects of confounding fac-
tors. Statistical analysis was performed using SPSS software 
(version 20.0; SPSS Korea, Seoul, Korea), and P <0.05 was con-
sidered to indicate statistical significance.
Results
1. Demographic characteristics and vital signs
Between November 2007 and November 2011, a total of 602 
adult patients (aged >15 years) visited the ED due to septic 
shock. Among these, 115 patients who did not fit our inclusion 
criteria were excluded. Sixteen patients were transferred to 
another hospital and four patients were discharged because 
they did not want to be hospitalized. Thirty-one patients were 
excluded because they or their families had established DNR 
status. Thus, a total of 436 patients who received SSC bundles 
were included in these analyses. 
Patients’ demographic characteristics and initial vital signs 
are shown in Table 1. The mean age was 64.75 ± 14.5 years and 
52.75% (230/436) patients were male. The vital signs of surviv-
ing patients and those who died were compared. For 7-day 
mortality, body temperature was significantly higher in survi-
vors than in patients who died (37.99 ± 1.37 vs. 37.25 ± 1.44, P = 
0.004). Central venous pressure was significantly lower in sur-
viving patients (7.64 ± 4.2 vs. 9.56 ± 4.57, P = 0.004). For 28-day 
mortality, MAP was higher in survivors than in patients who 
died (60.56 ± 11.19 vs. 56.49 ± 12.54, P = 0.01). Body tempera-
ture was higher in patients who survived (38 ± 1.37 vs. 37.51 ± 
1.46, P = 0.011), and CVP was lower in those who survived (7.52 
± 4.12 vs. 9.38 ± 4.75, P = 0.002) for 28-day mortality. 
2. Site of infection and causative pathogen
Pneumonia was the most common infection (28.21%, 
123/436), followed by urinary tract infection (25.92%, 113/436; 
Table 2). Causative organisms were identified in 240 patients 
(Table 2). Extended-spectrum β-lactamase (ESBL) non-pro-
ducing Escherichia coli was the most common organism 
(35.7%, 99/277). The second most common causative organ-
ism was ESBL non-producing Klebsiella pneumoniae (16.6%, 
46/277). 
3. Treatment process and clinical outcomes
Several modalities were used to treat septic shock (Table 3). 
Vasopressors were used in 428 (98.4%) patients. A total of 220 
(50.5%) patients received packed red blood cell (RBC) trans-
fusion, and 176 (40.4%) patients received insulin therapy. Cor-
ticosteroids and antithrombin III were used in 158 (36.2%) 
and 44 (10.1%) patients, respectively. Ventilator care and he-
modialysis treatment were conducted in 118 (27.1%) and 59 
(13.5%) patients, respectively. Initial antibiotic treatments 
were considered to be appropriate in 200/436 (46%) patients. 
EGDT endpoints were achieved successfully within 6 h in 
344/436 (78.9%) cases.
The mean duration of hospitalization was 14 (9 to 27) days. 
The 7- and 28-day mortality rates were 7.1% (31/436) and 14% 
(61/436), respectively.
4. Mortality risk factors
In the univariate analysis, 7-day mortality was found to be re-
lated to CVP (P = 0.017), Sequential organ failure assessment 
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Table 1. Demographic and clinical characteristics of the 436 patients at the time of surviving sepsis campaign bundle initiation 
Characteristics Total (n=436)
7 day mortality 28 day mortality
Alive (n=405) Death (n=31) P-value Alive (n=375) Death (n=61) P-value
Male sex 230 (52.75) 209 (51.6) 21 (67.74) 0.083 188 (50.13) 42 (68.85) 0.007
Age (mean ± SD, years) 64.75 ± 14.5 64.57 ± 14.6 67.23 ± 13 0.325 64.53 ± 14.7 66.11 ± 13.2 0.43
BMI (mean ± SD, kg/m2) 24.06 ± 18.24 24.16 ± 18.86 22.85 ± 5.54 <.001 23.25 ± 14.18 29.06 ± 33.6 0.188
Underlying diseases
  Congestive heart failure 17 (3.9) 16 (3.95) 1 (3.23) >.999 15 (4) 2 (3.28) >.999
  Peripheral vascular disease 4 (0.92) 3 (0.74) 1 (3.23) 0.256 3 (0.8) 1 (1.64) 0.454
  Cerebrovascular disease 55 (12.61) 51 (12.59) 4 (12.9) >.999 49 (13.07) 6 (9.84) 0.677
  Hypertension 288 (66.06) 176 (43.46) 112 (38.71) 0.607 165 (44) 23 (37.7) 0.357
  Coronary disease 30 (6.88) 28 (6.91) 2 (6.45) >.999 27 (7.2) 3(4.92) 0.784
  Lung disease 56 (12.84) 52 (12.84) 4 (12.9) >.999 4 (1.07) 3 (4.92) 0.06
  Autoimmune disease 10 (2.29) 9 (2.22) 1 (3.23) 0.526 50 (13.33) 6 (9.84) 0.449
  Liver disease 44 (10.09) 40 (9.88) 4 (12.9) 0.538 8 (2.13) 2 (3.28) 0.637
  Diabetes mellitus 121 (27.75) 115 (28.4) 6 (19.35) 0.279 109 (29.07) 12 (19.67) 0.129
  Hemiplegia 12 (2.75) 11 (2.72) 1 (3.23) 0.592 11 (2.93) 1 (1.64) >.999
  Renal disease 28 (6.42) 27 (6.68) 1 (3.23) 0.71 26 (6.95) 2 (3.28) 0.402
  Cancer 168 (38.53) 155 (38.27) 13 (41.94) 0.686 142 (37.87) 26 (42.62) 0.479
Vital signs
  Systolic blood pressure 
  (mean ±S D,  mmHg)
78.24 ± 16.33 78.52 ± 16.07 74.61 ± 19.37 0.2 78.96 ± 16.12 73.84 ± 17.05 0.023
  Diastolic blood pressure 
  (mean ± SD,  mmHg)
50.86 ± 10.49 51.12 ± 10.25 47.48 ± 12.97 0.063 51.36 ± 10.28 47.82 ± 11.34 0.014
  Mean blood pressure 
  (mean ± SD,  mmHg)
59.99 ± 11.46 60.26 ± 11.18 56.53 ± 14.49 0.171 60.56 ± 11.19 56.49 ± 12.54 0.01
  Heart rate (mean ± SD,  bpm) 104.66 ± 23.21 104.9 ± 23.27 101.2 ± 22.47 0.384 104.2 ± 22.49 107.6 ± 27.28 0.363
  Respiratory rate (mean ± SD,  bpm) 19.63 ± 4.3 19.6 ± 4.31 20 ± 4.14 0.62 19.58 ± 4.31 19.97 ± 4.26 0.51
  Body temperature 
  (mean ± SD, °C)
37.93 ± 1.39 37.99 ± 1.37 37.25 ± 1.44 0.004 38 ± 1.37 37.51 ± 1.46 0.011
  Central blood pressure 
  (mean ± SD,  mmHg)
7.78 ± 4.25 7.64 ± 4.2 9.56 ± 4.57 0.017 7.52 ± 4.12 9.38 ± 4.75 0.002
Severity score
  SOFA 8.41 ± 2.9 8.16 ± 2.73 11.74 ± 2.94 <0.001 7.92 ± 2.59 11.41 ± 2.87 <0.001
  APACHE II 18.29 ± 6.78 17.80 ± 6.47 24.87 ± 7.57 <0.001 17.36 ± 6.16 24.28 ± 7.59 <0.001
Laboratory data
WBC (median, interquartile 
range, mm3)
11,670 
(5,115 to 16,790)
12,120 
(5,610 to 16,960)
3,210
 (1,180 to 15,025)
0.046 12,040
 (5,820 to 16,480)
7,970
 (1,660 to 21,030)
0.45
Hemoglobin (median, interquar-
tile range, g/dL)
11.9 (10.3 to 13.3) 11.9 (10.4 to 13.2) 11.5 (8.5 to 14.5) 0.683 11.8 (10.4 to 13.3) 11.9 (9.4 to 13.3) 0.995
Hematocrit 
(median, interquartile range, %)
35.2 (30.6 to 39.3) 35.1 (30.7 to 39.2) 35.6 (26.5 to 44.7) 0.489 35 (30.7 to 39.25) 35.9 (30.2 to 40.1) 0.557
Platelet (median, interquartile 
range, mm3)
181k 
(103k to 277k)
186k
(114k to 278k)
93k
 (59.5k to 175.5k)
0.001 193k
(122k to 281.5k)
97k
(52k to 188k)
<0.001
ESR (median, interquartile range, 
mm/hr)
47 (22 to 78) 48 (24 to 79.25) 31 (11.5 to 59.5) 0.018 48 (25 to 79) 34 (11 to 66) 0.15
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(SOFA) score (P <0.001), APACHE II score (P <0.001), low white 
blood cell count (P = 0.046), low platelet count (P = 0.001), low 
erythrocyte sedimentation rate (P = 0.018), low estimated glo-
merular filtration rate (eGFR; P <0.001), high aspartate amino-
transferase (AST) concentration (P = 0.011), low albumin con-
centration (P = 0.005), high lactate level (P <0.001), low 
antithrombin III level (P = 0.001), hemodialysis (P <0.001), ven-
tilator care (P <0.001), and transfusion (P <0.001). In multivari-
ate analysis, high lactate level (odds ratio [OR], 1.286; 95% 
confidence interval [CI], 1.016–1.627; P = 0.036) and low eGFR 
(OR, 0.953; 95% CI, 0.913–0.996; P = 0.032) were found to be in-
dependently related to 7-day mortality (Table 4).
In univariate analysis, 28-day mortality was found to be relat-
ed to systolic blood pressure (P = 0.023), diastolic blood pres-
sure (P = 0.014), MAP (P = 0.01), CVP (P = 0.002), body tem-
perature (P = 0.011), SOFA score (P <0.001), APACHE II score 
(P <0.001), low platelet count (P <0.001), high blood urea nitro-
gen level (P = 0.008), low eGFR (P <0.001), high AST concen-
tration (P = 0.003), low albumin level (P <0.001), high potassi-
um level (P = 0.003), low total carbon dioxide level (P = 0.001), 
high C-reactive protein level (P = 0.004), high lactate level (P 
<0.001), low antithrombin III level (P = 0.001), prolonged acti-
vated partial thromboplastin time (P = 0.035), transfusion (P 
<0.001), ventilator care (P <0.001) and hemodialysis (P <0.001). 
Table 1. Continued
Characteristics Total (n=436)
7 day mortality 28 day mortality
Alive (n=405) Death (n=31) P-value Alive (n=375) Death (n=61) P-value
BUN (median, interquartile range, 
mg/dL)
27 
(18.4 to 40.2)
25.9
 (17.5 to 38.8)
39.4
 (27.85 to 58.7)
0.073 24.3
 (17.2 to 37.5)
41.7
 (28.4 to 60.5)
0.008
Creatinine (median, interquartile 
range, mg/dL)
1.5 (1 to 2.4) 1.5 (1 to 2.3) 2.5 (1.9 to 3.65) 0.267 1.4 (1 to 2.2) 2.5 (1.7 to 3.5) 0.332
Estimated GFR (mean±SD,  mL/
min/1.73 m2)
52.53 ± 30.09 54.18 ± 30.12 30.92 ± 19.67 <0.001 55.54 ± 30.15 34 ± 22.1 <0.001
AST (median, interquartile range, 
IU/L)
35 (22 to 81) 35 (22 to 78) 57 (25 to 197) 0.011 34 (21 to 72.5) 60 (28 to 210) 0.003
ALT (median, interquartile range, 
IU/L)
25 (14 to 48) 24 (14 to 45) 38 (20.5 to 76) 0.248 23 (14 to 43) 33 (18 to 67) 0.088
Total bilirubin (median, interquar-
tile range, mg/dL)
0.9 (0.5 to 1.6) 0.9 (0.5 to 1.5) 1.1 (0.45 to 2.3) 0.105 0.9 (0.55 to 1.4) 1.1 (0.4 to 2.3) 0.082
Glucose (median, interquartile 
range, mg/dL)
133
(103 to 180)
134
(106 to 182.5)
102
(56 to 163)
0.471 134
(106 to 181)
124
(80 to 179.5)
0.811
Albumin (mean±SD, g/dL) 3.2  ±  0.71 3.23  ±  0.71 2.85  ±  0.6 0.005 3.29  ±  0.7 2.66  ±  0.56 <0.001
Na (mean±SD, mmol/L) 134.1  ±  6.43 134.4  ±  6.51 134.58  ±  5.29 0.878 134.5  ±  6.36 133.84  ±  6.85 0.451
K (mean±SD, mmol/L) 4.13  ±  0.86 4.11  ±  0.85 4.37  ±  0.98 0.094 4.06  ±  0.77 4.54  ±  1.21 0.003
Cl (mean±SD, mmol/L) 99.55 ±  6.98 99.66  ±  6.99 98.16  ±  6.76 0.246 99.78  ±  6.86 98.15  ±  7.54 0.09
tCO2 (mean±SD, mmol/L) 18.03  ±  5.32 18.22  ±  5.05 15.65  ±  7.75 0.079 18.47  ±  4.9 15.38  ±  6.88 0.001
CRP (median, interquartile range, 
mg/L)
137
(67.5 to 225.49)
134
(63.38 to 221.62)
171.77
(97.23 to 286.74)
0.053 130.02
(61.3 to 218.61)
178.32
(95.95 to 280)
0.004
Lactate (mean±SD, mmol/L) 3.91  ±  3.28 3.66  ±  3.02 7.31  ±  4.53 <0.001 3.45  ±  2.77 6.79  ±  4.56 <0.001
D-dimer (median, interquartile 
range,  ng/mL)
1945.5
(726 to 4401.75)
1,390
(713 to 3,262)
5,170
(843 to 14,718)
0.084 1,377
(693.75 to 3199.75)
3179.5
(818.25 to 7,794)
0.185
Antithrombin III (mean±SD,  %) 60.28  ±  20.19 63  ±  18.03 44.63  ±  25.07 0.001 63.56  ±  18.17 48.793  ±  22.95 0.001
Prothrombin time (mean±SD, INR) 1.31  ±  0.86 1.27  ±  0.74 1.77  ±  1.78 0.129 1.27  ±  0.76 1.54  ±  1.3 0.113
aPTT (mean±SD,  sec) 31.53  ±  9.92 31.27  ±  9.46 34.89  ±  14.5 0.181 31  ±  9.18 34.78  ±  13.23 0.035
Data are frequencies and percentages in parentheses, unless otherwise indicated. 
BMI, body mass index; SOFA, sequential organ failure assessment; APACHE, acute physiology and chronic health evaluation; WBC, white blood cell; ESR, erythrocyte 
sedimentation rate; BUN, blood urea nitrogen; GFR, glomerular filtration rate; AST, aspartate aminotransferase; ALT, alanine transaminase; CRP, C-reactive protein; INR, 
International Normalized Ratio; aPTT, activated partial thromboplastin time.
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Table 2. Suspected site of infection and causative pathogen in patients treated with surviving sepsis campaign bundles
Characteristics
Total 
(n=436)
7 day mortality 28 day mortality
Alive (n=405) Death (n=31) P-value Alive (n=375) Death (n=61) P-value
Suspected site of infection
Laboratory-confirmed blood stream 
infection
8 (1.83%) 6 (1.5%) 2 (6.5%) 0.105 4 (1.1%) 4 (6.6%) 0.016
Clinical sepsis 38 (8.7%) 37 (9.1%) 1 (3.2%) 0.503 35 (9.3%) 3 (4.9%) 0.333
Pneumonia 123 (28.2%) 108 (26.7%) 15 (48.4%) 0.013 96 (25.6%) 27 (44.3%) 0.005
Symptomatic urinary tract infection 113 (25.9%) 111 (27.4%) 2 (6.5%) 0.009 109 (29.1%) 4 (6.6%) <0.001
Other infection of the urinary tract 1 (0.2%) 1 (0.2%) 0 (0%) >0.999 1 (0.3%) 0 (0%) >0.999
Joint or bursa infection 3 (0.69%) 3 (0.7%) 0 (0%) >0.999 2 (0.5%) 1 (1.6%) 0.364
Endocarditis 1 (0.2%) 1 (0.2%) 0 (0%) >0.999 1 (0.3%) 0 (0%) >0.999
Mediastinitis 1 (0.2%) 1 (0.2%) 0 (0%) >0.999 1 (0.3%) 0 (0%) >0.999
Meningitis or ventriculitis 1 (0.2%) 1 (0.2%) 0 (0%) >0.999 1 (0.3%) 0 (0%) >0.999
Eye, ear, nose, throat, and mouth 
infection
2 (0.5%) 2 (0.5%) 0 (0%) >0.999 2 (0.5%) 0 (0%) >0.999
Gastrointestinal tract infection 44 (10.1%) 43 (10.6%) 1 (3.2%) 0.347 39 (10.4%) 5 (8.2%) 0.818
Intraabdominal infection 65 (14.9%) 62 (15.3%) 3 (9.7%) 0.600 56 (14.9%) 9 (14.8%) >0.999
Other infection of the low respiratory 
tract
1 (0.2%) 1 (0.2%) 0 (0%) >0.999 1 (0.3%) 0 (0%) >0.999
Infections of reproductive tract 3 (0.7%) 3 (0.7%) 0 (0%) >0.999 3 (0.8%) 0 (0%) >0.999
Skin and soft tissue infection 19 (4.4%) 14 (3.5%) 5 (16.1%) 0.007 13 (3.5%) 6 (9.8%) 0.036
Systemic infection 9 (2.1%) 8 (2.0%) 1 (3.2%) 0.488 8 (2.1%) 1 (1.6%) >0.999
Other 4 (0.9%) 3 (0.7%) 1 (3.2%) 0.256 3 (0.8%) 1 (1.6%) 0.454
Causative pathogen
MSSA 11 (4%) 10 (3.9%) 1 (4.3%) 0.560 10 (4.2%) 1 (2.4%) 0.657
MRSA 5 (1.8%) 4 (1.6%) 1 (4.3%) 0.310 3 (1.3%) 2 (4.9%) 0.146
MSCNS 1 (0.4%) 1 (0.4%) 0 (0%) >0.999 1 (0.4%) 0 (0%) >0.999
MRCNS 11 (4%) 10 (3.9%) 1 (4.3%) >0.999 7 (3%) 4 (9.8%) >0.999
MSSE 1 (0.4%) 1 (0.4%) 0 (0%) >0.999 1 (0.4%) 0 (0%) >0.999
MRSE 6 (2.2%) 6 (2.4%) 0 (0%) >0.999 5 (2.1%) 1 (2.4%) >0.999
Enterococcus faecium 9 (3.2%) 7 (2.8%) 2 (8.7%) >0.999 7 (3%) 2 (4.9%) 0.620
Enterococcus faecalis 5 (1.8%) 5 (2%) 0 (0%) 0.310 5 (2.1%) 0 (0%) 0.531
VRE 1 (0.4%) 1 (0.4%) 0 (0%) >0.999 1 (0.4%) 0 (0%) >0.999
Escherichia coli (ESBL-) 99 (35.7%) 95 (37.4%) 4 (17.4%) 0.659 91 (38.6%) 8 (19.5%) 0.623
Escherichia coli (ESBL+) 10 (3.6%) 10 (3.9%) 0 (0%) 0.526 9 (3.8%) 1 (2.4%) 0.152
Klebsiella pneumoniae (ESBL-) 46 (16.6%) 44 (17.3%) 2 (8.7%) >0.999 40 (16.9%) 6 (14.6%) >0.999
Klebsiella pneumoniae (ESBL+) 6 (2.2%) 6 (2.4%) 0 (0%) >0.999 6 (2.5%) 0 (0%) >0.999
Citrobacter sp. 2 (0.7%) 2 (0.8%) 0 (0%) >0.999 2 (0.8%) 0 (0%) >0.999
Pseudomonas aeruginosa 23 (8.3%) 17 (6.7%) 6 (26.1%) 0.219 16 (6.8%) 7 (17.1%) >0.999
Acinetobacterbaumannii 7 (2.5%) 6 (2.4%) 1 (4.3%) >0.999 6 (2.5%) 1 (2.4%) >0.999
Streptococcus pneumoniae 10 (3.6%) 9 (3.5%) 1 (4.3%) 0.154 7 (3%) 3 (7.3%) 0.152
Proteus mirabilis 9 (3.2%) 9 (3.5%) 0 (0%) 0.488 8 (3.4%) 1 (2.4%) 0.118
Other 15 (5.4%) 11 (4.3%) 4 (17.4%) 0.614 11 (4.7%) 4 (9.8%) >0.999
No growth 196 (45%) 184 (45.4%) 21 (38.7%) 0.711 171 (45.6%) 25 (41%) 0.679
Data are frequencies and percentages in parentheses. 
MSSA, methicillin-sensitive Staphylococcus aureus ; MRSA, methicillin-resistant Staphylococcus aureus ; MSCNS, methicillin-sensitive coagulase-negative staphylococci ; 
MRCNS, methicillin-resistant coagulase-negative staphylococci ; MSSE, methicillin-sensitive Staphylococcus epidermidis ; MRSE, methicillin-resistant Staphylococcus epi-
dermidis ; VRE, vancomycin-resistant enterococci ; ESBL, extended-spectrum β-lactamase.
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In multivariate analysis, high lactate level (OR, 1.346; 95% CI, 
1.083-1.673; P = 0.008) and high APACHE II score (OR, 1.153; 
95% CI, 1.029-1.293; P = 0.014) were found to be independently 
related to 28-day mortality (Table 4). 
Discussion
The growing number of patients with septic shock and in-
creased mortality requires changes in ED processes. In 2001, 
Rivers et al. [2] reported that the use of EGDT as a resuscita-
tion strategy reduced absolute in-hospital mortality by 16%. In 
2002, the European Society of Intensive Care Medicine, the 
International Sepsis Forum, and the Society of Critical Care 
Medicine launched the SSC. After 3 years, they published the 
initial guidelines in 2004; revised versions were published in 
2008 [18] and 2012 [19]. SSC is a performance improvement 
process that emphasizes the early detection of infection and 
institution of antibiotic therapy. Although the SSC resuscita-
tion bundle has been proven to successfully reduce mortality, 
it could not be used widely in many developing countries be-
cause of a lack of resources. Our institute participated in a 
multi-national, multi-organ study that implemented SSC re-
suscitation bundles, and education [6]. Our hospital adopted 
a multidisciplinary sepsis team model of implementation. The 
resuscitation bundle was initiated in the ED and completed in 
the ICU. We examined short-term mortality and risk factors of 
septic shock in this hospital under implementation of the 
team model of resuscitation.
In our multivariate analysis, high lactate level was inde-
pendently associated with 7- and 28-day mortality. Blood lac-
tate levels are considered to reflect the magnitude of anaero-
bic metabolism, and their use is recommended in guidelines 
and included in resuscitation bundles as an indicator of organ 
hypoperfusion and shock, although the etiology of lactate ele-
vation is open to dispute. Lactate is known to be a target end-
point, an indicator of severity, and a predictor of short- and 
long-term mortality. Elevation of lactate is thought to be asso-
ciated with poor outcomes, such as increased mortality [20]. 
Nguyen et al. [21] suggested that resuscitation bundles includ-
ing lactate clearance are more effective than those that do not 
include this component. Although high lactate level was sig-
nificantly associated with mortality in the present study, this 
finding is limited in that only initial lactate levels were mea-
sured and no data on lactate clearance were obtained. Low 
eGFR was independently associated with 7-day mortality in 
this study, as in several other studies [22, 23]. We could not 
figure out the possible explanation on the association be-
tween lower ESR and mortality. The APACHE II scoring sys-
tem is a good tool for the prediction of sepsis severity in criti-
cally ill patients [10]. In our study, higher APACHE II scores 
were associated with higher 28-day mortality (P = 0.014). Rad-
ical calculation of the APACHE II score is derived from the 
worst values in the first 24 h after ICU admission [24]. Howev-
er, in this study, we met our patients in the ED first, facilitating 
the collection of physiological data on admission. A retrospec-
tive cohort study by Ho et al. [24] suggested that the admission 
Table 3. Treatment process and clinical outcomes
No of patients (%)
Treatment process
Packed RBC transfusion 220 (50.5)
Ventilator care 118 (27.1)
Hemodialysis 59 (13.5)
Corticosteroid administration 158 (36.2)
Antithrombin III therapy 44 (10.1)
IV immunoglobulin therapy 18 (4.1)
Insulin therapy 176 (40.4)
Appropriate initial antibiotic treatment 200 (46)
  Vasopressor administration 428 (98.4)
  Achievement of SSC bundle goals 344 (78.9)
Clinical outcome
Hospital length of stay (median inter-
quartile range, days)
14 (9 to 27)
7 day mortality 7.1 (31/436)
28 day mortality 14 (61/436)
Data are frequencies and percentages in parentheses, unless otherwise indicated.
RBC, red blood cell; SSC, surviving sepsis campaign.
Table 4. Independent risk factors for mortality of patients with severe 
sepsis or septic shock treated with surviving sepsis campaign bundles by 
Cox’s regression analysis
Variables Odds ratio (95% CI) P-value
7-day mortality
Age 1.020 (0.958-1.085) 0.543
Lactate 1.286 (1.016-1.627) 0.036
eGFR 0.953 (0.913-0.996) 0.032
Antithrombin III 0.967 (0.926-1.009) 0.123
Central venous pressure 1.057 (0.909-1.229) 0.473
APACHE II score 1.127 (0.992-1.281) 0.065
28-day mortality
Age 1.019 (0.967-1.074) 0.483
Lactate 1.346 (1.083-1.673) 0.008
eGFR 0.973 (0.943-1.004) 0.084
Antithrombin III 0.976 (0.941-1.013) 0.197
Central venous pressure 1.005 (0.881-1.146) 0.946
APACHE II score 1.153 (1.029-1.293) 0.014
Per one increase in age, level, pressure, or score. 
eGFR, estimated glomerular filtration rate; APACHE, acute physiology and chronic 
health evaluation.
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APACHE II model is a potential alternative to the worst 24 h 
APACHE II model in patients in critical condition but without 
trauma. Park et al., in their prospective, multi-center, observa-
tional study, investigated about risk factors for mortality in pa-
tients with community-acquired severe sepsis and septic 
shock. In the multivariate analysis, cancer, APACHE II score, 
SOFA score and metabolic dysfunction were independent 
clinical factors for gender-related in-hospital mortality in their 
study [25]. APACHE II score was also independent risk factor 
for mortality in our study, but other factors were different. Be-
cause of differences in study methods and design including 
only community-acquired, maybe such different results have 
occured. Drumheller et al., in their retrospective, single-center 
observational cohort study of severe sepsis and septic shock 
patient in ED, identified that age, active cancer, diabetes, DNR 
status on ED arrival, temperature never >38°C, glucose <60 
mg/dL, intubation, and lactate clearance were independently 
associated with in-hospital mortality [25]. However, their 
study also has differences with our study in patient character-
istics.
Puskarichet et al. [4] reported a 1-year mortality rate of 37% 
(77/206) in patients with severe sepsis and septic shock who 
were treated at the Carolinas Medical Center. A 2009 study 
showed that mortality decreased from 27% to 19% after EGDT 
implementation in the pre-intervention phase [3]. The 7- and 
28-day mortality rates in our study (7.11% and 14%) were low-
er than in previous studies. The lower mortality in our cohort 
groups might indicate that they were less critically ill than 
groups evaluated in other studies. Otherwise, the low mortali-
ty rate observed in our hospital may be due to the Korean 
health care system or the practices of our institution. The Ko-
rean health care system offers easy access to medical care to 
all patients, irrespective of health insurance status. Moreover, 
our hospital is located in an urban area with a high socioeco-
nomic level. These differences emphasize the need for each 
institution to assess its own population. The mortality rate in 
our study was lower than other study from South Korea [26]. 
The reasons for this difference might be caused by differences 
in the focus of infection and causative pathogens. For exam-
ple, in this study, ESBL-negative E. coli which can be treated 
easily was much frequently isentified as a causative pathogen 
than other study [26].
The most common focus of infection in our study cohort 
was pneumonia. Urinary tract infection was also a common 
focus of infection in patients who survived, but was not a main 
cause of death. The most common causative microbiologic or-
ganism in the group who survived was ESBL-negative E. coli. 
Few microbiologic sources were identified in pneumonia cas-
es, but many were identified in urinary tract infection cases. E. 
coli seemed to be the most common causative organism in 
survivors who received SSC bundles.
Park et al., in their large observational study, found that pa-
tients who received RBC transfusion had higher 28-day and 
in-hospital mortality rates than those who did not. But they 
found that after adjusting for possible confounding factors 
and severity of illness, RBC transfusion was associated with 
lower risk of 7-day, 28-day, and in-hospital mortality [27]. In 
our study, transfusion was risk factor of 7-day and 28-day 
mortality. Probably, the different results came out from not 
adjusting such confounding factors.
Our study has several limitations, such as its retrospective 
design and the use of a single medical center as the source of 
data. Our retrospective evaluation prevented the examination 
of risk factors in a randomized situation. Usually, the APACHE 
II score is determined using the worst 24-h score after admis-
sion, but we first met our patients in the ED and collected 
physiological data on admission. Thus, we applied the 
APACHE II score obtained at the time of admission. And re-
cently there is emerging on suspicion on the need for the pro-
tocol-based bundle therapy. But our sepsis team model of im-
plementation make treatment faster and might reduce 
mortality of patients. In this study, we did not evaluate the dif-
ferences of outcomes and risk factors according to the achieve-
ment of EGDT goal, and we did not measure the adherence on 
SSC bundles. In addition, we used the previous definition of 
septic shock, and further study based on the revised definition 
of septic shock should be performed. In conclusion, the risk of 
mortality of septic shock patients remains high in patients with 
high lactate levels and acute kidney injury.
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